Product data sheet

MedKoo Cat#: 584430 Name: SR 16832 CAS: 2088135-12-8 Chemical Formula: $C_{17}H_{12}ClN_3O_4$ Exact Mass: 357.0516 Molecular Weight: 357.75	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.
	In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:
SR 16832 is a dual site PPARγ inhibitor that acts at orthosteric and allosteric sites in the ligand binding domain and inhibits binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonists GW 9662 and T 0070907.

2. CoA, QC data, SDS, and handling instruction
SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	17.89	50

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.80 mL	13.98 mL	27.95 mL
5 mM	0.56 mL	2.80 mL	5.59 mL
10 mM	0.28 mL	1.40 mL	2.80 mL
50 mM	0.06 mL	0.28 mL	0.56 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator
Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study
In vitro study

1. Brust R, Lin H, Fuhrmann J, Asteian A, Kamenecka TM, Kojetin DJ. Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor. ACS Chem Biol. 2017 Apr 21;12(4):969-978. doi: 10.1021/acschembio.6b01015. Epub 2017 Feb 16. PMID: 28165718; PMCID: PMC5652320.

In vivo study

To be determined

7. Bioactivity
Biological target:

SR 16832 inhibits MRL20-induced allosteric activation of PPARγ in a reporter assay using HEK293T cells when used at a concentration of 5 μM. SR 16832 also reduces basal activity of PPARγ and inhibits binding of docosahexaenoic acid (DHA) to PPARγ in a time-resolved FRET (TR-FRET) assay.

In vitro activity

Compounds such as SR 16832 may be useful chemical tools to use as a dual-site bitopic orthosteric and allosteric covalent inhibitor of ligand binding to PPARγ. This study identified SR 16832 as a dual-site covalent inhibitor of PPARγ transcription by PPARγ-binding

Product data sheet

ligands. SR 16832 better inhibits binding of rosiglitazone and may better inhibit binding of endogenous PPARγ ligands compared to orthosteric covalent antagonists.

Reference: ACS Chem Biol. 2017 Apr 21;12(4):969-978. https://pubmed.ncbi.nlm.nih.gov/28165718/

In vivo activity

To be determined

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.